Bernanke Spurs Stocks
Health Care: Drugs
Nektar Therapeutics Inc. (NKTR: NASDAQ)
$9.62 -0.11 | -1.13%
05/22/13 - 12:19 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 9.73 |
| 52 Week High | 11.34 |
| 52 Week Low | 5.65 |
| Avg. Daily Vol. (Mil) | 0.90 |
| Beta (3 year) | 1.83 |
| Share Related Items | |
| Mkt Cap (Mil) | 1,124.04 |
| Shares Out (Mil) | 115.52 |
| Float (Mil) | 91.32 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.90 |
| Current Ratio | 3.20 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 13.03 |
| Price/Book | 0.00 |
| Price/Cash Flow | -8.20 |
| Per Share Data | |
| Earnings | -1.62 |
| Sales | 0.75 |
| Book Value | 0.00 |
| Cash Flow | -1.18 |
| Business Summary | |
|---|---|
| Nektar Therapeutics, Inc, is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. | |
| General Information | |
| 455 Mission Bay Boulevard So
San Francisco, CA 94158 |
|
| www.nektar.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 433 | |
| CEO: Mr. Howard W. Robin | |
| Short Interest | |
| Current Month (Mil) | 8.90 |
| Previous Month (Mil) | 9.50 |
| Short Interest Ratio (Days) | 10.60 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -33.80 |
| Return on Investments | -113.00 |
| Profitability | |
| Gross Margin | 78.30 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with NKTR
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorBreakout Stocks Of The Week...
- Contributor22 Biopharma Stocks With Br...
- Contributor10 Health Care Stocks With ...
- Contributor10 Mid-Caps With Upside
- Contributor10 Pharma Stocks With Upside
- ProDriehaus Capital
- UserSUPRATRADE 7 Top Stocks for...
- UserSUPRATRADE 10 Stock Picks F...
Latest NKTR Headlines from TheStreet
- Nektar Therapeutics Enters Oversold Territory (NKTR) 05.10.13 | 12:05 pm
- 4 Stocks Under $10 Spiking Higher 02.22.13 | 03:02 pm
- 5 Stocks Poised for Breakouts 02.01.13 | 01:02 pm
- J.P. Morgan Healthcare Confab Live Blog Day Three 01.09.13 | 10:01 am
- Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab 01.04.13 | 08:01 am
- A Buysider's Preview of Biotech's Biggest Conference 01.02.13 | 07:01 am
- AstraZeneca, Nektar Opioid Constipation Drug May Have Failed Phase III Study 11.13.12 | 10:11 am
- FDA Places New Heart-Safety Hurdle in Path of Opioid Constipation Drugs 11.12.12 | 10:11 am
- 21 Most Volatile Biopharma Stocks Closing Out 2012 11.05.12 | 06:11 am
- 5 Stocks Poised for Breakouts 09.28.12 | 01:09 pm
Press Releases for NKTR
- Bayer Initiates Phase III Trial Of Investigational Inhaled Amikacin Solution (BAY41-6551T) In Mechanically Ventilated Patients With Gram-negative Pneumonia - PR Newswire 04.16.13 | 05:04 am
- Nektar Therapeutics To Present At The 33rd Annual Cowen And Company Healthcare Conference In Boston - PR Newswire 03.01.13 | 04:03 pm
- AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation - PR Newswire 02.26.13 | 06:02 am
- Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 31st Annual J.P. Morgan Healthcare Conference In San Francisco, CA - PR Newswire 01.04.13 | 08:01 am
- Nektar To Announce Financial Results For The Third Quarter Of 2012 On Tuesday, November 13, 2012, After Close Of U.S.-Based Financial Markets - PR Newswire 11.06.12 | 05:11 pm
- Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The UBS 2012 Global Life Sciences Conference In New York City - PR Newswire 09.13.12 | 09:09 am
- Nektar To Announce Financial Results For The Second Quarter Of 2012 On Thursday, August 9, 2012, After Close Of U.S.-Based Financial Markets - PR Newswire 08.02.12 | 03:08 pm
- Nektar Therapeutics Announces Private Placement Of $125 Million Of Senior Secured Notes Due In 2017 - PR Newswire 07.10.12 | 08:07 am
- Nektar To Host Investor And Analyst R&D Day In New York City - PR Newswire 04.10.12 | 08:04 am
- Nektar Doses First Subjects In Phase 1 Clinical Study Evaluating NKTR-192, A New Short-Acting Opioid Molecule For The Treatment Of Acute Pain - PR Newswire 04.02.12 | 08:04 am
Partner Headlines for NKTR
- UPDATE: Bank of America Lowers Nektar Therapeutics PO, Maintains Underperform - Benzinga 11.13.12 | 09:11 am
- UPDATE: Jefferies & Company Downgrades Nektar Therapeutics to Hold, Lowers PT - Benzinga 11.12.12 | 09:11 am
- Nektar Therapeutics Says Got Positive Data from Phase 1a Study of NKTR-192 - Benzinga 09.18.12 | 09:09 am
- Long Undervalued, Is Alkermes Still A Bargain? - Seeking Alpha 03.30.12 | 09:03 am
- The Age Of Personalized Medicine Has Arrived - Seeking Alpha 03.08.12 | 09:03 am
- Company News for March 1, 2012 - Corporate Summary - Zacks 03.01.12 | 10:03 am
- What's It Going To Take To Get Salix Cheap? - Seeking Alpha 02.29.12 | 08:02 am
- Nektar Therapeutics Presents Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer - Benzinga 09.10.11 | 04:09 pm
- 10 Stocks With Bullish Momentum Backed By Strong Top Line Growth - Seeking Alpha 08.24.11 | 08:08 am
- 14 Oversold Stocks Trading Near Lows but Being Bought Up by the Smart Money - Seeking Alpha 07.12.11 | 09:07 am
